Hepion Pharmaceuticals Inc (HEPA) News

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat

EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...

Form EFFECT - Notice of Effectiveness

Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model

EDISON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...

Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules

EDISON, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...

Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference

EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...

New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program

- 850 cancer cell lines screened in Broad Institute’s PRISM lab - - Rencofilstat active on 220 cancer cell...

Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer

- Research study demonstrates regulation of chromatin structure and cancer gene expression – - Findings to...

Form 4 - Statement of changes in beneficial ownership of securities

Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis

– Proteomics analysis showed that rencofilstat improved aberrant protein profiles in IPF tissues – – Superior...

Form 8-K - Current report

Hepion Pharmaceuticals Announces Management Changes

EDISON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...

Form 8-K - Current report

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023

- Preclinical studies demonstrate rencofilstat may protect against NASH/NAFLD, shift the liver transcriptome...